Bio Roundup: CBO’s Praise, Celgene’s Shock, Trump’s Opioid Plan & More

Bio Roundup: CBO’s Praise, Celgene’s Shock, Trump’s Opioid Plan & More

(Page 2 of 2)

Phase 3 studies, CEO Martin Tolar told Xconomy. The FDA granted fast-track status to ALZ-801, a reformulated version of a previously shelved drug tramiprosate.

—Seven months after raising $45.5 million in a Series D financing, Waltham, MA-based Arsanis filed for an initial public stock offering to support clinical testing of its experimental drug to prevent pneumonia infections.

—In other IPO news, Burlington, MA-based scPharmaceuticals filed to go public to finance commercialization of its lead product candidate, Furoscix, an injectable form of the high blood pressure drug furosemide.

—Belgium-based Ablynx (NASDAQ: ABLX) raised $200 million in its U.S. stock market debut.

—For $150 million upfront, Incyte (NASDAQ: INCY) acquired global rights to an experimental antibody therapy from MacroGenomics, which is part of a class of cancer treatments called PD-1 inhibitors.

—John Hood, who led the development of blood cancer drug fedratinib before it was acquired by pharma giant Sanofi (NYSE: SNY), raised $90 million in financing to resume work on the experimental treatment with a new company, Impact Biomedicines. Sanofi stopped working on the drug four years ago after safety concerns arose.

—- Finch Therapeutics merged with Crestovo in a combination of Massachusetts microbiome companies. The new entity, Finch Therapeutics Group, is based in Somerville and led by Mark Smith, who was president and CEO of the former Finch.

—New York-based Y-mAbs Therapeutics raised $50M that the company will use to bring its lead antibody cancer drug into late-stage clinical testing.

Frank Vinluan contributed to this report.

Image by Joe Flintham via a Creative Commons license.

Share the Article